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Neonatal alloimmune thrombocytopenia is most commonly due to transplacental passage of
maternal anti-HPA 1a antibodies. A prospective study was carried out to evaluate the pattern
and quantity of maternal anti-HPA 1a antibodies in order to predict the level of thrombocy-
topenia in the neonates.
Design and Methods
A monoclonal antibody immobilization of platelet antigen assay was used to detect antibod-
ies in maternal samples from 1,990 HPA 1bb women. HLA DRB3*0101 typing was performed
in all immunized women by sequencing the HLA DRB3 gene when present.
Results
Primary immunization more often took place in connection with delivery than during the first
pregnancy. There was a strong correlation between maternal antibody levels and the platelet
counts in the newborn (R2=0.49, p<0.001). A maternal antibody level above 3.0 IU/mL meas-
ured in gestational week 22 or 34 had a diagnostic sensitivity and specificity of 93% and
63%, respectively, for predicting the grade of neonatal thrombocytopenia. The women who
were negative for HLA DRB3*0101 had significantly lower anti-HPA 1a antibody levels than
those who were HLA DRB3*0101 positive (p<0.007). In contrast to primigravida, in whom
anti-HPA 1a antibody levels increased during pregnancy, the antibody level decreased in 92
of 147 women who had been pregnant previously (P92 or more of 147 = 0.003). The anti-HPA 1a
antibody level regularly increased after delivery.
Conclusions
Maternal anti-HPA 1a antibody levels in weeks 22 and 34 of pregnancy are good predictors
of the degree of thrombocytopenia in the newborn both in the first and subsequent pregnan-
cies. Most mothers became immunized at the time of delivery.
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Introduction
Neonatal alloimmune thrombocytopenia (NAIT) in
Caucasians is most commonly due to transplacental pas-
sage of maternal anti-HPA 1a antibodies (85%),1 and is a
condition that resembles hemolytic disease of the new-
born. Complications of NAIT, such as intracranial hem-
orrhage, leading to neurological disability or death, have
been reported to occur in 10-30% of affected babies.2-4 At
present, an accurate measurement of fetal platelet count
can only be achieved through high-risk sampling of
umbilical cord blood. Several prospective studies have
shown a correlation between anti-HPA 1a antibody level
and severity of thrombocytopenia in the newborn.4-7 A
correlation was also found in two retrospective studies,8,9
whereas one other retrospective study did not find such
a relationship.10 In a recent trial, we documented that
identification of women with anti-HPA 1a antibodies,
close clinical follow-up during pregnancy, elective
Cesarean section and transfusion of compatible platelets
to neonates with severe thrombocytopenia, reduce
NAIT-related morbidity and mortality.11 The main pur-
pose of this study was to describe the natural course of
HPA 1a alloimmunity by recording maternal anti-HPA 1a
antibody levels longitudinally throughout pregnancy and
after delivery. We also studied the relationship between
the platelet counts in the neonates and both the level of
maternal anti-HPA 1a antibodies at delivery and the
weighted mean of anti-HPA 1a antibody levels to which
the neonates had been exposed during pregnancy.
Finally, we tried to identify a maternal anti-HPA 1a anti-
body level that could be used as a predictive parameter
for severe thrombocytopenia in the newborn.
Design and Methods
Samples
HPA 1a negative pregnant women (1,990 women)
were tested for anti-HPA 1a antibodies approximately
every fourth week during pregnancy.11 Preliminary data
from the first 232 HPA 1a negative women included in
this study have been published previously.5 Anti-HPA 1a
antibodies were also analyzed and quantified around 6
weeks post-delivery in approximately 65% of the cases.
Immediately after birth, the platelet count was deter-
mined in umbilical cord blood and/or from a capillary
blood sample from the neonate. We defined severe
thrombocytopenia as a platelet count <50×109/L and
moderate thrombocytopenia as a platelet count  between
50×109/L and 149×109/L.
This study was approved by the Regional Committee
for Medical Research Ethics, North Norway (approval
number: P-REK V 13/1995). 
HPA 1 typing 
HPA 1 phenotyping was performed either by an HPA
1a typing assay (DiaMed AG, Switzerland) in accor-
dance with the manufacturer’s instructions, or by flow
cytometry, as previously described,12 using a fluoroescein
isothiocyanate conjugated anti-CD61 antibody reacting
specifically with the HPA 1a epitope13 (clone SZ21,
Immunotech, Marseilles, France). All HPA 1a-negative
samples were genotyped by a 5´nuclease assay or melt-
ing curve analysis.14,15
Detection and quantitation of antibodies 
Anti-HPA 1a antibodies were searched for using either
a modification of the technique known as monoclonal
antibody immobilization of platelet antigen assay
(MAIPA)16-18 or the indirect platelet suspension immuno-
fluorescence test (PIFT) analyzed by flow cytometry.19
Plasma samples from HPA 1a negative pregnant women
from the northern part of Norway were screened for
antibodies using MAIPA, whereas those from HPA 1a
negative pregnant women from the southern part of
Norway were screened for antibodies using the PIFT
and, if antibodies were present, the samples were sent to
the Department of Immunology and Transfusion
Medicine, University Hospital of North Norway for
identification of the antibodies by MAIPA. Anti-CD61,
clone Y2/51 (Dako A/S, Glostrup, Denmark) was used to
immobilize the glycoprotein GPIIb/IIIa complex for anti-
body detection. 
For quantitation of anti-HPA 1a antibodies, a reference
sample from one woman with a high level of anti-HPA
1a antibodies was used in two-fold dilutions from 1:2 to
1:64, to create a linear standard curve. The antibody con-
centration in this sample was equivalent to 15 IU/mL of
the international anti-HPA 1a standard, (NIBSC product
code 03/152, Hertfordshire, UK). Samples with high lev-
els of antibodies were diluted so that the antibody con-
centration fell in the linear part of the standard curve. A
negative sample was also run in parallel. The cut-off
level for a positive test was an optical density of 0.1 at
490 nm. The weighted mean of anti-HPA 1a antibody
levels during pregnancy was determined by calculating
the area under the curve (AUC) describing the maternal
anti-HPA 1a antibody level over time divided by the
number of weeks of antibody measurements. The repro-
ducibility of the MAIPA method was determined by cal-
culating the critical difference from repeated intra-assay
measurements of 14 samples with different amounts of
anti-HPA 1a antibodies. The critical difference was
found to be 30% and only changes in antibody levels
exceeding this value were considered as clinically signif-
icant. An automatic microparticle enzyme linked
immunoassay was used to detect Rubella antibodies
(AxSYM RUBELLA IgG kit, Abbott Diagnostics
Division, Abbott Park, IL, USA).
HLA DRB3 typing 
HLA DRB3 typing was performed by sequencing the
HLA DRB3 gene when present. The intron-located
primers previously described by Kotsch et al.20 were used
for the polymerase chain reaction (PCR). The PCR prod-
uct was sequenced in an ABI PRISM 3730 DNA analyz-
er (Applied Biosystems, Foster City, USA). DNA from
women whose sequencing results were difficult to inter-
pret, and from HLA DRB3 negative women, were sent
to the Tissue Typing Laboratory, Institute of Immunol-
ogy, Rikshospitalet University Hospital, for HLA DRB3
typing by PCR-sequence-specific oligonucleotide probes
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and high resolution PCR-sequence-specific primers
(GenoVision, Vienna, Austria).
Statistics 
One way analysis of variance (ANOVA) was used to
compare mean antibody levels in women who gave birth
to neonates with normal platelet counts or moderate and
severe NAIT. Twin births were regarded as one birth in the
statistical calculations as the platelet counts of the two
pairs of twins included in this study were in the same cat-
egory (normal platelet counts in one pair and severe
thrombocytopenia in the other). The paired sample t-test
was used to compare anti-HPA 1a antibody levels before
and after delivery. The Mann-Whitney U test was used to
compare the anti-HPA 1a antibody levels in HLA
DRB3*0101 positive and negative women. 
To examine the association between maternal anti-HPA
1a antibody level and platelet count in the neonates, we
used power fit regression analysis. The platelet count (Y) is
given by the formula Y=b0×xb1 where x is the anti-HPA 1a
antibody level and b0 and b1 are constants. 
We used a receiver operating characteristic (ROC) curve
to evaluate maternal anti-HPA 1a level as a predictive
parameter for severe NAIT.21 An AUC of 1.0 indicates
complete discrimination, whereas an AUC of 0.5 or less
means absence of discrimination. The theoretically best
cut-off value was calculated using Pythagoras’ theorem as
described by Peat and Barton.22 The critical difference of
the MAIPA indicated the minimal clinical relevant change
in antibody level and was calculated according to Gluer et
al.23 The probability (p) of declining antibody levels during
a pregnancy in a multigravida was calculated according to
the binomial distributions (two-tailed test). Our calcula-
tions were based on the assumption that p=0.5.
Maternal antibody patterns and the number of children
with severe NAIT were analyzed using the χ2-test and cal-
culation of relative risk (RR) with 95% confidence inter-
vals (CI) when appropriate. The binomial sample distribu-
tion was calculated using an interactive calculator at the
VassarStats website for statistical calculations.24 Other sta-
tistical calculations were performed with SPSS for
Windows computer software (Version 11.5, SPSS Inc.,




The median gestational age with the 95% CI at which
the first sample was taken was week 13+5 (week 12+6-
week 14+4). The median (95% CI) gestational age at the
time the last sample was taken was week 36+4 (week
36+0-week 36+6). The median (95% CI) gestational ages
for the samples obtained around weeks 22 and 34 were
22+2 (week 21+6-week 22+5) and 34+0 (week 33+5-
week 34+3), respectively.
Maternal anti-HPA 1a antibody level and platelet
count in the newborn
Antibodies were detected in 170 pregnancies delivered
by Cesarean section, as previously reported,11 and in
three pregnancies ending in vaginal deliveries. Twenty-
four of these pregnancies were included in an earlier
study.5 In one of the 170 pregnancies a moderate amount
of anti-HPA 1a antibodies was detected in the first sam-
ple (gestational week 34), but no anti-HPA 1a antibodies
were found at the time of delivery. Due to lack of plas-
ma for quantitative analysis in the first sample obtained,
this pregnancy was excluded from our analysis. In 161
pregnancies, there was an HPA 1 incompatibility
between the mother and the child.
Both maternal anti-HPA 1a antibody level at delivery
and the weighted mean of anti-HPA 1a antibody levels
during pregnancy were significantly higher in women
who gave birth to severely thrombocytopenic children
than in those who gave birth to children with moderate
thrombocytopenia or a normal platelet count (Table 1).
Regression analysis showed that there was a strong asso-
ciation between maternal anti-HPA 1a antibody level
and the platelet count in the neonates (Figure 1).
Anti-HPA 1 antibody level as a predictor of severe
NAIT
We then assessed the potential of maternal anti-HPA
1a antibody level for predicting severe NAIT (Figure 2).
The theoretically best cut-off value for prediction of
thrombocytopenia in the fetus was 3.0 IU/mL for anti-
body measurements close to delivery (sensitivity 81%,
specificity 80%), and 5.0 IU/mL for the weighted mean
of antibody levels (sensitivity 76%, specificity 81%).
When using only one measurement close to delivery
(week 34) and a cut-off level of 3.0 IU/mL, 10 of 55
pregnancies would have been lost from intervention in
the Norwegian screening and intervention study.11
However, when two antibody measurements were
performed (at weeks 22 and 34) and a cut-off level of
3.0 IU/mL was used to identify cases at risk of NAIT,
the sensitivity increased to 93% but the specificity
decreased to 63% (Table 2). Using this approach, the
number of false negative cases (maternal anti-HPA 1a
level < 3.0 IU/mL, but severe NAIT) could be reduced
from 10/55 neonates to 4/55. 
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Table 1. Mean of maternal antibody levels at delivery and weight-
ed mean of antibody levels measured in 161 non-compatible preg-
nancies.
Number Mean antibody Weighted mean of 
of neonates level at delivery, antibody levels,
IU/mL (95% CI) IU/mL (95% CI)
Platelet count 55 23.7 (15.0-32.3)* 22.0 (14.7-29.3)*
[<50×109/L
Platelet count 33 4.2 (1.7-6.8)* 5.3 (2.7-7.9)*
[50-149×109/L
Platelet count 75 1.4 (0.3-2.5)* 2.4 (1.1-3.7)*
[>150×109/L
Total 163
The 161 non-compatible pregnancies including two twin pregnancies. One pair of
twins had platelet counts <50×109/L, and the other pair had platelet counts
>150x109/L. *There was a statistically significant difference in antibody levels
between the three groups; p<0.0001.
 
For 17 pregnancies (in 14 women) there was infor-
mation of a previous child with severe NAIT. In seven
of these 17 pregnancies, the baby had severe NAIT. An
obstetric history of NAIT had a weaker positive pre-
dictive value than maternal anti-HPA 1a antibody level
(Table 2).
Quantitation of anti-HPA 1a antibodies during
pregnancy
Fourteen of 172 pregnancies in women with anti-HPA
1a antibodies were first pregnancies. One woman,
alleged to be in her first pregnancy, was excluded
because of elements of uncertainty. This woman had a
high level of anti-HPA 1a antibodies in gestational week
7 but the antibodies were no longer present in week 20,
suggesting immunization prior to the pregnancy. In 9 of
the 13 remaining women, the antibodies were
detectable in gestational week 22. The other four had
detectable antibodies in gestational weeks 24, 26, 34 and
36. These 13 women had increasing anti-HPA 1a anti-
body levels towards term (Figure 3A). In the last sample
before term the mean (±95% CI) anti-HPA 1a antibody
level was 7.5 (±4.5) IU/mL whereas the weighted mean
(±95% CI) of antibody level was 3.4 (±1.8) IU/mL. Six
(46%) of these 13 first pregnancies culminanted with the
birth of a child with severe thrombocytopenia.
In 92 of the 147 incompatible pregnancies in multi-
gravida, there was a decline in antibody level during
pregnancy (Figure 3B). The number of pregnancies with
a decreasing antibody level was significantly higher than
the number of pregnancies with no decline in antibody
level (P92or more of 147=0.003). The mean (±95% CI) antibody
level in the 92 pregnancies in which antibody levels
declined was 15.4 (±6.1) IU/mL in the first sample
obtained and decreased to 5.6 (±2.4) IU/mL at the end of
pregnancy, giving a weighted mean anti-HPA 1a anti-
body level of 9.6 (±4.2) IU/mL. Altogether 29 (32%) chil-
dren in this group were severely thrombocytopenic. 
For the pregnancies in which the antibody levels
dropped to below 3.0 IU/mL by the end of pregnancy,
the relative risk of severe thrombocytopenia in the
neonates was 0.24 (95% CI: 0.13-0.45) relative to the
group in which the antibody level in last sample was
>3.0 IU/mL. In 33 pregnancies, no antibodies could be
detected in the last sample before delivery. None of the
babies born from these pregnancies were severely
thrombocytopenic although seven had moderately
reduced platelet counts (67×109/L-115×109/L). 
In 25 multigravida, the antibody level increased from a
mean of 11.6 (±6.1) IU/mL in the first trimester to 29.5
(±16.2) IU/mL in the last sample obtained before deliv-
ery, which was equivalent to a weighted mean of anti-
HPA 1a antibody levels of 16.1 (±6.1) IU/mL (Figure 3C).
Twelve (48%) children in this group had severe throm-
bocytopenia. In 24 multigravida, the antibody level
remained low, fluctuating slightly throughout the preg-
nancy (Figure 3D). None of the children born from these
women were thrombocytopenic. 
Eleven of the pregnancies in multigravida were HPA
Ibb compatible. The women who carried an HPA 1a
negative fetus had persistently high levels of antibodies
throughout pregnancy (Figure 3E). None of the compati-
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Figure 1. The association between maternal antibody level and
platelet count in the newborn. (A) Maternal antibody level at the
end of pregnancy and platelet count in the newborn. The equation
of the regression curve is: Y = 76 × x-0.28. R2 =0.49; p<0.001. (B)
Weighted mean of anti-HPA 1a antibody levels during pregnancy
and the platelet count in the newborn. The equation of the regres-
sion curve is: Y =127 × x-0.45. R2=0.45; p<0.001. 
Figure 2. The receiver operating characteristic (ROC) curve showing
the diagnostic performance of maternal anti-HPA 1a antibody level
as a predictor of severe severe neonatal autoimmune thrombo-
cythemia. The unbroken black line represents maternal antibody
level close to delivery (week 34), and the hatched gray line the
weighted mean. The unbroken gray reference line represents
absence of discrimination. The calculated area under the curve
was 0.87 (95% CI: 0.82-0.92) for maternal antibody levels close to
delivery, and 0.85 (95% CI: 0.79-0.91) for the weighted mean of
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ble children had thrombocytopenia. Figure 4 gives an
overview of the different maternal anti-HPA 1a antibody
patterns in the women and the outcome of their
neonates.
In addition to these antibody patterns, another pattern
was seen in six pregnancies in which an initially high
level of anti-HPA 1a antibodies decreased by 20-30%
during the course of the pregnancy. Since the decreases
were less than the calculated critical difference, these six
pregnancies were excluded from the large group of
multigravida with decreasing antibody levels. Five of the
children delivered from these six pregnancies had severe
thrombocytopenia.
The relative risk of giving birth to a child with severe
NAIT was zero if the anti-HPA 1a antibody level was
>3.0 IU/mL in first trimester and subsequently became
undetectable during gestation (multigravida, 0/15) com-
pared to those pregnancies in which no anti-HPA 1a was
detected in the first sample, but in which immunization
took place during pregnancy and the anti-HPA 1a anti-
body level increased to >3.0 IU/mL (mainly first preg-
nancies, 6/10).
In all but six of the 147 pregnancies in women who
had been pregnant previously, anti-HPA 1a antibodies
were detected in the first sample obtained, usually in the
first trimester. In the six pregnancies without detectable
antibodies in the first samples, antibodies were detected
in gestational weeks 14 (n=1), 20 (n=2), 22 (n=1), 24
(n=1) and 38 (n=1).
Post-partum levels of anti-HPA 1a
Anti-HPA 1a antibody levels were measured in sam-
ples taken approximately 6 weeks post-partum from 120
of the pregnancies with antibodies detectable during
gestation. The post-partum antibody levels were signifi-
cantly higher than those at the time of delivery in all
non-compatible pregnancies (Figure 3A-D). The post-
partum antibody levels in compatible pregnancies were
not significantly higher than those at delivery (Figure
3E).
Post-partum samples from about 65% of the women
who did not have detectable anti-HPA 1a antibodies dur-
ing pregnancy were also analyzed for such antibodies
after delivery. In 39 cases no anti-HPA 1a antibodies
could be detected at delivery, but antibodies were pres-
ent approximately 6 weeks later (Figure 3F). By adjusting
for the whole study group we estimate that approxi-
mately 60 women became anti-HPA 1a positive after
delivery.
Anti-HPA 1a antibody level and HLA DRB3*0101
status
Approximately 90% of the immunized women
expressed HLA DRB3*0101.11 The mean (±95%CI)
maternal antibody level close to delivery was 10.3 (±3.6)
IU/mL in HLA DRB3*0101 positive women, compared
to 0.4 (±0.3) IU/mL in HLA DRB3*0101 negative women
(p=0.007). Two HLA DRB3*0101 negative women gave
birth to children with moderate thrombocytopenia
(platelet count: 59×109/L and 94×109/L). There were no
differences in the HLA DRB3*0101 status between
women immunized early in pregnancy, those immu-
nized in the last trimester of pregnancy and those with
anti-HPA 1a antibodies detected 6 weeks after delivery.
Anti-rubella antibodies
Samples from ten women were examined antibodies
against rubella. In all cases anti-rubella antibodies were
present and their levels stable throughout gestation, con-
trasting with the anti-HPA 1a antibody levels that either
decreased (n= 8) or increased (n=2) in these pregnancies
(data not shown).
Discussion
A correlation between the level of antibodies to the HPA
1a antigen and severity of NAIT has been described by
several investigators.4-9 Results from the present work,
including 161 non-compatible pregnancies, further sub-
stantiate this relationship. The theoretically best antibody
cut-off level for predicting an outcome appraises sensitivi-
ty and specificity equally, but is not necessarily the opti-
mal level for use in clinical practice since the consequences
of false-negative and false-positive results may be very dif-
ferent. Although maternal antibody levels decreased in the
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Table 2. The diagnostic sensitivity and specificity, as well as positive and negative predictive values of maternal antibody level and obstet-
ric history as predictors of severe neonatal autoimmune thrombocythemia (neonatal platelet count <50×109/L). 
Predictor Neonatal Neonatal Diagnostic Diagnostic Positive Negative
platelet count platelet count sensitivity specificity predictive value predictive value
<50×109/L >50×109/L (95% CI) (95% CI) (95% CI) (95% CI)
Anti-HPA 1a > 3.0 IU/mL  in either 50* 42
week 22 or 34 93% 63% 54% 95%
Anti-HPA 1a ≤ 3.0 IU/mL  4 72*
(81-89%) (54-72%) (43-63%) (86-98%)
in both weeks 22 and 34
Previous history of NAIT 7 10 13% 92% 41% 70%
No previous history of NAIT 47* 109* (6-26%) (84-96%) (19-66%) (61-77%)
The calculation was based on the data from the 168 pregnancies for which antibody levels were assayed in both gestational weeks 22 and 34. *Including one twin preg-
nancy.   
majority of non-compatible subsequent pregnancies, such
that several women had low levels of anti-HPA 1a anti-
bodies at term, some of these women still gave birth to
children with severe NAIT. However, by measuring anti-
body levels twice, at approximately gestational weeks 22
and 34, and using a cut-off level of 3.0 IU/mL, the diagnos-
tic sensitivity for predicting severe thrombocytopenia of
the newborn was 93%. An additional advantage of meas-
uring antibody levels early and late in pregnancy, rather
than only once closer to delivery, is that appropriate clini-
cal follow-up and possible interventions can be planned if
the anti-HPA 1a level in the first sample is very high. 
The weighted mean of antibody levels as a predictive
parameter cannot discriminate between those women
with antibody levels rising from zero to >3.0 IU/mL, and
those with antibody levels decreasing to below 3.0 IU/mL.
We have shown that women in the former group have a
high risk of giving birth to children with severe NAIT,
whereas the risk in the latter group is low. This indicates
that the antibody level close to delivery may be the best
predictive parameter for women who have not previously
been pregnant. 
Recently, Ghevaert et al.10 published the results of a ret-
rospective study in which no correlation could be found
between the maternal anti-HPA 1a antibody level and
platelet count in the neonates. The explanation for the
divergence between their results and ours may be differ-
ences in selection criteria. In our study, women were
included prospectively after HPA 1 typing, whereas
Ghevaert and his group mainly included women retro-
spectively on the basis of their having had a child with a
bleeding tendency. They also included some women with
a previous history of a child with NAIT.
It was shown in a European collaborative study on the
antenatal management of feto-maternal alloimmune
thrombocytopenia25 that a previous child with NAIT was
the best predictor of subsequent pregnancies at risk of
NAIT. Although one could argue that a previous history of
thrombocytopenia may have been missed in our study,
and could have biased the analyses, we found that women
may have a severely affected child even if their previous
child or children did not have clinical signs of NAIT.
Moreover, women who gave birth to children with severe
NAIT in one pregnancy did not necessarily give birth to an
affected child in the next one.11 Our results indicate that
the maternal anti-HPA 1a antibody level has equal predic-
tive power as the obstetric history.
Antibody responses to the HPA 1a antigen have been
reported to be restricted to women who are HLA
DRB3*0101 positive.26 In our study, however, approxi-
mately 10% of the immunized women did not have this
particular HLA class II antigen.11 Quantitation of the anti-
HPA 1a levels revealed that these were significantly lower
in HLA DRB3*0101 negative women, than in women who
were HLA DRB3*0101 positive, probably reflecting that
the antigen presented in the context of HLA DRB3*0101 is
more immunogenic than peptides presented by other HLA
class II molecules. 
Altogether, anti-HPA 1a antibodies were detected in 172
pregnancies from a population of 1,990 HPA 1a negative
women. Only 13 of these 172 pregnancies were first preg-
nancies. This is surprising, since severe NAIT has been
reported to occur frequently in first born children.2 On the
other hand, it was calculated that 60 women seroconvert-
ed after delivery. This may indicate that the primary
immune response was established in association with, or
after, the delivery, most probably due to feto-maternal
bleeding. Thirteen primigravida and 6 multigravida con-
verted from an antibody negative to antibody positive sta-
tus during pregnancy. The time of conversion could not be
determined for the remaining multigravida, because anti-
HPA 1a was detected in the first sample collected during
pregnancy. Although we cannot exclude the possibility
that our MAIPA technique is not sufficiently sensitive to
Anti-HPA 1a antibodies and NAIT
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Figure 3. Different patterns of anti-HPA
1a level (mean ± 95% CI) during preg-
nancy (median gestational week of the
first and last samples) and after deliv-
ery. (A) First pregnancies. (B)
Pregnancies in women who had previ-
ously been pregnant and who had
decreasing anti-HPA 1a antibody lev-
els. (C) Pregnancies in women who had
previously been pregnant and who had
increasing anti-HPA 1a antibody levels.
(D) Pregnancies in women who had pre-
viously been pregnant and who had per-
sistently low levels of anti-HPA 1a anti-
body. (E) Pregnancies in women who
had previously been pregnant and who
gave birth to an HPA 1a negative child.
(F) Pregnancies in which anti-HPA 1a
antibodies were detected post-partum
but not during pregnancy. The number
of pregnancies is indicated in parenthe-
ses. Antibody levels were higher post-
partum than at delivery in all non-com-
patible pregnancies [p=0.010 in group
(A), p<0.0001 in group (B), p=0.004 in
group (C) and p=0.026 in group (D)]. No
increase in antibody level was found
between delivery and 6 weeks post-
partum in compatible pregnancies
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detect low levels of maternal anti-HPA 1a antibodies pres-
ent during a first pregnancy, our observations do suggest
that immunization occurs after delivery in a relatively high
proportion of HPA 1a negative women giving birth to HPA
1a positive children. 
Our results suggest that the immunization pattern for
NAIT in many women is similar to that occuring in
hemolytic disease of the newborn. It is not, therefore,
unlikely that immunization against HPA 1a could be pre-
vented in a similar way as for the RhD antigen, i.e. by
administration of anti-HPA 1a antibodies after any event
associated with an increased risk of feto-maternal bleed-
ing, such as an abortion, amniocentesis or delivery. Either
purified polyclonal human anti-HPA 1a immunoglobulin
G or recombinant human HPA 1a antibodies could be used
for this purpose.27
We and others have previously reported that anti-HPA
1a antibody levels decrease throughout pregnancy in
women who have had a previous pregnancy.9,28-30 The fact
that the levels of antibodies to the rubella antigen were
stable during pregnancy disproves the hypothesis that the
decrease in anti-HPA 1a antibody levels could be due to
the normal hemodilution that occurs during pregnancy.
Furthermore, women with anti-HPA 1a antibodies and an
HPA 1a negative fetus did not experience decreasing anti-
HPA 1a levels during pregnancy. The decrease in antibody
levels in multiparous women may also have implications
when evaluating possible treatment with high-dose intra-
venous immunoglobulin in women who have previously
had a child with NAIT. The natural decline in anti-HPA 1a
antibody levels in multiparous women to a low level with
no clinical significance may explain why the incidence of
children with NAIT is lower in these women. Indeed,
when the maternal anti-HPA 1a antibody level decreased
and became undetectable before delivery, there was a very
low risk of thrombocytopenia in the newborn. 
In conclusion, we have presented further evidence for
the strong association between maternal anti-HPA 1a anti-
body level and platelet count in the newborn. The preterm
antibody level has equal positive predictive value for NAIT
as obstetric history and a much higher diagnostic sensitiv-
ity. Expression of HLA DRB3*0101 seems to be a prereq-
uisite for producing clinically significant levels of anti-HPA
1a antibodies. In previously immunized women anti-HPA
1a antibody levels tend to decrease during pregnancy,
sometimes to undetectable levels. Immunization seems to
occur more often after delivery than during the first non-
compatible pregnancy.
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Figure 4. A flow diagram showing the maternal anti-HPA 1a antibody patterns and the outcome of the neonates (severe neonatal autoim-
mune thrombocythemia or not). *As post-delivery samples were obtained from approximately 65% of the women, the numbers given have
been adjusted to reflect the expected numbers of the whole group.° One woman was excluded because it was unclear whether she really
was a primipara. She had a high level of anti-HPA 1a antibodies in week 7 of her pregnancy and the antibodies disappeared by gestational
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